LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Crinetics Pharmaceuticals Inc

Avatud

SektorTervishoid

31.44 1.06

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

30.59

Max

31.6

Põhinäitajad

By Trading Economics

Sissetulek

-16M

-97M

Müük

361K

361K

Aktsiakasum

-1.04

Kasumimarginaal

-26,807.202

Töötajad

437

EBITDA

-6.9M

-94M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+148.96% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

7. aug 2025

Turustatistika

By TradingEconomics

Turukapital

-41M

3.1B

Eelmine avamishind

30.38

Eelmine sulgemishind

31.44

Uudiste sentiment

By Acuity

51%

49%

314 / 382 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Crinetics Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

15. mai 2025, 22:52 UTC

Tulu
Suurimad hinnamuutused turgudel

Virgin Galactic Shares Rise on Commercial Spaceflight Plans, Narrower 1Q Loss

15. mai 2025, 20:37 UTC

Peamised uudised
Tulu

Applied Materials Logs Higher 2Q Profit, Revenue as Customer Demand Remains Unchanged

16. mai 2025, 00:00 UTC

Market Talk

Xero Bull Stays Positive on Cost Outlook -- Market Talk

15. mai 2025, 23:47 UTC

Market Talk

Gold Consolidates; Likely Supported by Signs of Disinflation -- Market Talk

15. mai 2025, 23:38 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15. mai 2025, 23:38 UTC

Market Talk

Nikkei May Edge Higher, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

15. mai 2025, 23:14 UTC

Peamised uudised

Walmart Becomes Biggest Retailer Yet to Pass Through Tariff Price Increases -- 4th Update

15. mai 2025, 22:46 UTC

Peamised uudised
Omandamised, ülevõtmised, äriostud

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15. mai 2025, 22:46 UTC

Omandamised, ülevõtmised, äriostud

Bayer Working With Restructuring Advisers Latham, AlixPartners to Explore Options for Monsanto -- WSJ

15. mai 2025, 22:46 UTC

Omandamised, ülevõtmised, äriostud

Bayer Exec Says Company Committed to Resolving Roundup Lawsuits in 18 Months -- WSJ

15. mai 2025, 22:46 UTC

Omandamised, ülevõtmised, äriostud

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15. mai 2025, 21:58 UTC

Tulu

Applied Materials Earnings Beat Expectations. Why the Stock Is Down. -- Barrons.com

15. mai 2025, 21:24 UTC

Tulu

Cava's Earnings Beat Expectations. Growth Was Strong Despite Tariff Fears. -- Barrons.com

15. mai 2025, 20:56 UTC

Market Talk

U.S. Spending Downturn Could Lie Ahead -- Market Talk

15. mai 2025, 20:54 UTC

Market Talk
Tulu

Applied Materials CFO Says Demand Stable Despite Tariffs, Macro -- Market Talk

15. mai 2025, 20:54 UTC

Tulu

Applied Materials Investing to Support Semiconductor Market of More Than $1T by End of Decade, Financial Chief Says

15. mai 2025, 20:51 UTC

Tulu

Applied Materials Financial Chief: Long-Term Secular Growth Drivers Remain Intact

15. mai 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

15. mai 2025, 20:50 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Sells Financial Stocks, Doubles Constellation Stake, Holds Steady on Apple -- WSJ

15. mai 2025, 20:50 UTC

Tulu

Applied Materials' Customer Investments Continue at Expected Rate and Pace, Financial Chief Says

15. mai 2025, 20:47 UTC

Tulu

Applied Materials Not Currently Seeing Large Changes in Customer Demand, CEO Says

15. mai 2025, 20:47 UTC

Tulu

Applied Materials Sees Revenue From Advanced DRAM Customers to Grow 40% in FY25, CEO Says

15. mai 2025, 20:47 UTC

Tulu

Applied Materials Grew Faster Than Peers in Markets Outside China in 2Q, CEO Says

15. mai 2025, 20:47 UTC

Tulu

Applied Materials Underperformed Market in China in 2Q Due to Restrictions on U.S. Companies, CEO Says

15. mai 2025, 20:37 UTC

Tulu

SOS Ltd: Growth Was Fueled by Robust Domestic Demand and Expansion of Pdt Portfolio to Include Rubber and Coal >SOS

15. mai 2025, 20:37 UTC

Tulu

SOS Ltd: Cryptocurrency Mining Rev Declined to $9.3M From $18.9M in FY23, Dip Was Attributed to the Temporary Shutdown of Texas Mining Facility for Upgrades During 1H 2024 >SOS

15. mai 2025, 20:37 UTC

Tulu

SOS Ltd: FY24 Significant Yr-over-Yr Increase in Commodity Trading Rev, Which Soared to $214.3M FY24, 92.6% of Total Rev Up From 74.0% in FY23 >SOS

15. mai 2025, 20:37 UTC

Tulu

SOS Ltd: Cryptocurrency Mining Rev Halves as SOS Focuses on Facility Upgrades and Commodity Expansion >SOS

15. mai 2025, 20:26 UTC

Peamised uudised

Trump Presses Apple to Bring iPhone Manufacturing to America. Wall Street Shrugs. -- WSJ

15. mai 2025, 20:25 UTC

Tulu

Deere Stock Jumps on Guidance Cut. Here's Why. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Crinetics Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

148.96% tõus

12 kuu keskmine prognoos

Keskmine 77.7 USD  148.96%

Kõrge 100 USD

Madal 53 USD

Põhineb 11 Wall Streeti analüütiku instrumendi Crinetics Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

11 ratings

11

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

30.39 / 33.46Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Neutral Evidence

Sentiment

By Acuity

314 / 382 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.